FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Pierre Lindenmayer

Research Profile

Disorders

Chemicals & Drugs

Activities & Behaviors

Schizophrenic Psychology

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Jean-Pierre Lindenmayer; Anzalee Khan
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Ibrahim Turkoz; Cynthia A Bossie; Jean-Pierre Lindenmayer; Nina Schooler; Carla M Canuso
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Carla M Canuso; Nina R Schooler; Jennifer Carothers; Ibrahim Turkoz; Colette Kosik-Gonzalez; Cynthia A Bossie; David Walling; Jean-Pierre Lindenmayer
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Pierre Lindenmayer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Jean-Pierre Lindenmayer; Anzalee Khan
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Schizophrenia research 2011;125(2-3):267-77.
2011: Ibrahim Turkoz; Cynthia A Bossie; Jean-Pierre Lindenmayer; Nina Schooler; Carla M Canuso
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
BMC psychiatry 2011;11():21.
2010: Carla M Canuso; Nina R Schooler; Jennifer Carothers; Ibrahim Turkoz; Colette Kosik-Gonzalez; Cynthia A Bossie; David Walling; Jean-Pierre Lindenmayer
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
Journal of clinical psychopharmacology 2010;30(5):487-95.
2010: Robert C Smith; Jean-Pierre Lindenmayer; Qiaoyan Hu; Erin Kelly; Thomas F Viviano; James Cornwell; Sumathi Vaidhyanathaswamy; Santica Marcovina; John M Davis
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Schizophrenia research 2010;120(1-3):204-9.
2010: Carla M Canuso; Jean-Pierre Lindenmayer; Colette Kosik-Gonzalez; Ibrahim Turkoz; Jennifer Carothers; Cynthia A Bossie; Nina R Schooler
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
The Journal of clinical psychiatry 2010;71(5):587-98.
2009: Jean-Pierre Lindenmayer; Anzalee Khan; Deborah Wance; Neta Maccabee; Sashank Kaushik; Saurabh Kaushik
Outcome evaluation of a structured educational wellness program in patients with severe mental illness.
The Journal of clinical psychiatry 2009;70(10):1385-96.
2009: Sashank Kaushik; Neta Maccabee; Saurabh Kaushik; Jean-Pierre Lindenmayer
Activation induced by high-dose ziprasidone: a case report.
The Journal of clinical psychiatry 2009;70(9):1326-7.
2009: Rachel Neuhut; Jean-Pierre Lindenmayer; Raul Silva
Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review.
Journal of child and adolescent psychopharmacology 2009;19(4):415-22.
2009: Jean-Pierre Lindenmayer; Hong Liu-Seifert; Pandurang M Kulkarni; Bruce J Kinon; Virginia L Stauffer; Sara E Edwards; Lei Chen; David H Adams; Haya Ascher-Svanum; Peter F Buckley; Leslie Citrome; Jan Volavka
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.
The Journal of clinical psychiatry 2009;70(7):990-6.
2009: Robert C Smith; Jean-Pierre Lindenmayer; John M Davis; James Cornwell; Kathryn Noth; Sanjay Gupta; Henry Sershen; Abel Lajtha
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder.
Schizophrenia research 2009;110(1-3):149-55.
2009: Dara Y Cho; Jean-Pierre Lindenmayer
Aripiprazole-induced agitation after clozapine discontinuation: a case report.
The Journal of clinical psychiatry 2009;70(1):141-3.
2009: Carlos Saavedra-Velez; Anna Yusim; Deepti Anbarasan; Jean-Pierre Lindenmayer
Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
The Journal of clinical psychiatry 2009;70(1):104-12.
2008: Anna Yusim; Deepti Anbarasan; Carol Bernstein; Istvan Boksay; Michael Dulchin; Jean-Pierre Lindenmayer; Carlos Saavedra-Velez; Maksim Shapiro; Benjamin Sadock
Normal pressure hydrocephalus presenting as Othello syndrome: case presentation and review of the literature.
The American journal of psychiatry 2008;165(9):1119-25.
2008: Bruce J Kinon; Jan Volavka; Virginia Stauffer; Sara E Edwards; Hong Liu-Seifert; Lei Chen; David H Adams; Jean-Pierre Lindenmayer; Joseph P McEvoy; Peter F Buckley; Jeffrey A Lieberman; Herbert Y Meltzer; Daniel R. Wilson; Leslie Citrome
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
Journal of clinical psychopharmacology 2008;28(4):392-400.
2008: Michael Ciranni; Jean-Pierre Lindenmayer; Jeffrey Gold
Efficacy of molindone in treatment-refractory agitated schizophrenia: three case reports.
The Journal of clinical psychiatry 2008;69(6):1018-9.
2008: Jean-Pierre Lindenmayer; Susan Regina McGurk; Kim T Mueser; Anzalee Khan; Deborah Wance; Lisa Hoffman; Rosemarie Wolfe; Haiyi Xie
A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness.
Psychiatric services (Washington, D.C.) 2008;59(3):241-7.
2008: Sashank Kaushik; Anzalee Khan; Saurabh Kaushik; Jean-Pierre Lindenmayer
Interface for electronic data capture systems for clinical trials by optimal utilization of available hospital resources.
AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium 2008;():998.
2008: Jean-Pierre Lindenmayer; David Brown; Sherry Liu; Martin Brecher; Didier Meulien
The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
Psychopharmacology bulletin 2008;41(3):11-35.
2008: Jean-Pierre Lindenmayer; Cynthia A Bossie; Mary Kujawa; Young Zhu; Carla M Canuso
Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale.
Psychopathology 2008;41(4):264-70.
2007: Jean-Pierre Lindenmayer; Anzalee Khan; Adel Iskander; Maria T Abad; Benedicto Parker
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
The Journal of clinical psychiatry 2007;68(3):368-79.
2007: Jean-Pierre Lindenmayer; Akbar Khan; Mariëlle Eerdekens; Ilse Van Hove; Stuart Kushner
Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2007;17(2):138-44.
2007: Darcy Santor; Haya Ascher-Svanum; Jean-Pierre Lindenmayer; Robert Obenchain
Item response analysis of the Positive and Negative Syndrome Scale.
BMC psychiatry 2007;7():66.
2007: A Carlo Altamura; Emanuela Mundo; Roberta Bassetti; A Green; Jean-Pierre Lindenmayer; Larry Alphs; Herbert Y Meltzer
Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder.
Schizophrenia research 2007;89(1-3):140-6.
2006: Matthew Hoptman; Jan Volavka; Pal Czobor; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie Citrome; Brian Sheitman; Jean-Pierre Lindenmayer; Jeffrey A Lieberman; Robert Bilder
Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder.
The Journal of neuropsychiatry and clinical neurosciences 2006;18(4):509-15.
2005: Leslie Citrome; Ari Jaffe; Jerome Levine; Jean-Pierre Lindenmayer
Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.
The Journal of clinical psychiatry 2005;66(12):1512-6.
2005: Matthew Hoptman; Jan Volavka; Elisabeth M Weiss; Pal Czobor; Philip Szeszko; Guido Gerig; Miranda Chakos; Joseph Blocher; Leslie Citrome; Jean-Pierre Lindenmayer; Brian Sheitman; Jeffrey A Lieberman; Robert Bilder
Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder.
Psychiatry research 2005;140(2):133-45.
2005: Jean-Pierre Lindenmayer; Kathleen Jarboe; Cynthia A Bossie; Young Zhu; Angelika Mehnert; Robert A Lasser
Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone.
International clinical psychopharmacology 2005;20(4):213-21.
2005: Jan Volavka; Karen A Nolan; Linda Kline; Pal Czobor; Leslie Citrome; Brian Sheitman; Jean-Pierre Lindenmayer; Joseph McEvoy; Jeffrey A Lieberman
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
Schizophrenia research 2005;76(1):127-9.
2005: Robert C Smith; Jean-Pierre Lindenmayer; Nigel Bark; Jessy Warner-Cohen; Sumathi Vaidhyanathaswamy; Amaresh Khandat
Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2005;8(2):183-94.
2005: Karen A Nolan; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Jeffrey A Lieberman
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
Journal of psychiatric research 2005;39(1):109-15.
2004: Jean-Pierre Lindenmayer; Els Eerdekens; Sally A Berry; Mariëlle Eerdekens
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
The Journal of clinical psychiatry 2004;65(8):1084-9.
2004: Marc Bourgeois; Joel D Swendsen; Frederick Young; Xavier F Amador; Stefano Pini; Giovanni B Cassano; Jean-Pierre Lindenmayer; Chuanchieh Hsu; Larry Alphs; Herbert Y Meltzer
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial.
The American journal of psychiatry 2004;161(8):1494-6.
2004: Jean-Pierre Lindenmayer; Eileen Brown; Robert W Baker; Leslie M Schuh; Lixin Shao; Mauricio Tohen; Saeeduddin Ahmed; Virginia L Stauffer
An excitement subscale of the Positive and Negative Syndrome Scale.
Schizophrenia research 2004;68(2-3):331-7.
2004: Jan Volavka; James L Kennedy; Xingqun Ni; Pal Czobor; Karen A Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Jeffrey A Lieberman
COMT158 polymorphism and hostility.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2004;127B(1):28-9.
2004: Jan Volavka; Pal Czobor; Karen A Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Jeffrey A Lieberman
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Journal of clinical psychopharmacology 2004;24(2):225-8.
2004: Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
The Journal of clinical psychiatry 2004;65(4):551-6.
2004: Larry Alphs; Ravi Anand; M Zahur Islam; Herbert Y Meltzer; John M Kane; Ranga Krishnan; Alan I Green; Steven G Potkin; Guy Chouinard; Jean-Pierre Lindenmayer; Rob Kerwin
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.
Schizophrenia bulletin 2004;30(3):577-86.
2004: Jan Volavka; Pal Czobor; Thomas B Cooper; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Jeffrey A Lieberman
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
The Journal of clinical psychiatry 2004;65(1):57-61.
2003: Jean-Pierre Lindenmayer; Pal Czobor; Larry Alphs; Ann-Marie Nathan; Ravi Anand; Zahur Islam; James C-Y Chou
The InterSePT scale for suicidal thinking reliability and validity.
Schizophrenia research 2003;63(1-2):161-70.
2003: John M Kane; Mariëlle Eerdekens; Jean-Pierre Lindenmayer; Samuel J Keith; Michael Lesem; Keith Karcher
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
The American journal of psychiatry 2003;160(6):1125-32.
2003: Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Leslie Citrome; Brian Sheitman; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
The American journal of psychiatry 2003;160(2):290-6.
2003: Herbert Y Meltzer; Larry Alphs; Alan I Green; A Carlo Altamura; Ravi Anand; Alberto Bertoldi; Marc Bourgeois; Guy Chouinard; M Zahur Islam; John M Kane; Ranga Krishnan; Jean-Pierre Lindenmayer; Steven G Potkin
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Archives of general psychiatry 2003;60(1):82-91.
2002: Jean-Pierre Lindenmayer; Pal Czobor; Jan Volavka; Jeffrey A Lieberman; Leslie Citrome; Brian Sheitman; Miranda Chakos; Joseph P McEvoy
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
The Journal of clinical psychiatry 2002;63(10):931-5.
2002: Robert Bilder; Jan Volavka; Pal Czobor; Anil Malhotra; James L Kennedy; Xingqun Ni; Robert S Goldman; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Jeffrey A Lieberman
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.
Biological psychiatry 2002;52(7):701-7.
2002: Robert Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
The American journal of psychiatry 2002;159(6):1018-28.
2002: Pal Czobor; Jan Volavka; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Antipsychotic-induced weight gain and therapeutic response: a differential association.
Journal of clinical psychopharmacology 2002;22(3):244-51.
2002: Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
The American journal of psychiatry 2002;159(2):255-62.
2001: Daniel C Javitt; Gail Silipo; Angel Cienfuegos; AM Shelley; Nigel Bark; M Park; Jean-Pierre Lindenmayer; R Suckow; Stephen R Zukin
Adjunctive high-dose glycine in the treatment of schizophrenia.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2001;4(4):385-91.
2001: Leslie Citrome; Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Joseph McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Psychiatric services (Washington, D.C.) 2001;52(11):1510-4.
2001: Jean-Pierre Lindenmayer; Jan Volavka; J Lieberman; Brian Sheitman; Leslie Citrome; Miranda Chakos; Pal Czobor; B Parker; Adel Iskander
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Journal of clinical psychopharmacology 2001;21(4):448-53.
2001: Jean-Pierre Lindenmayer; R C Smith; A Singh; B Parker; E Chou; A Kotsaftis
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.
Journal of clinical psychopharmacology 2001;21(3):351-3.
2001: Jean-Pierre Lindenmayer; A M Nathan; Robert C Smith
Hyperglycemia associated with the use of atypical antipsychotics.
The Journal of clinical psychiatry 2001;62 Suppl 23():30-8.
2000: Jan Volavka; Thomas B Cooper; Pal Czobor; Jean-Pierre Lindenmayer; Leslie Citrome; Pavel Mohr; Nigel Bark
High-dose treatment with haloperidol: the effect of dose reduction.
Journal of clinical psychopharmacology 2000;20(2):252-6.
2000: Jean-Pierre Lindenmayer; A Kotsaftis
Use of sodium valproate in violent and aggressive behaviors: a critical review.
The Journal of clinical psychiatry 2000;61(2):123-8.
1998: Jean-Pierre Lindenmayer; Adel Iskander; M Park; F S Apergi; Pal Czobor; R Smith; D Allen
Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.
The Journal of clinical psychiatry 1998;59(10):521-7.
1998: E J Bartlett; Jonathan D Brodie; P Simkowitz; Ralf Schlösser; Stephen L Dewey; Jean-Pierre Lindenmayer; Henry Rusinek; Adam Wolkin; Robert Cancro; Wynne K Schiffer
Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
The American journal of psychiatry 1998;155(3):337-43.
1997: I Faisal; Jean-Pierre Lindenmayer; Z Taintor; Robert Cancro
Clozapine-benzodiazepine interactions.
The Journal of clinical psychiatry 1997;58(12):547-8.
1997: Jean-Pierre Lindenmayer; M Vital-Herne; Nigel Bark; S Grochowski; N Moynihan
Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
Biological psychiatry 1997;42(1):6-12.
1997: Jean-Pierre Lindenmayer; A E Negrón; S Shah; R Lowinger; Gary J Kennedy; Nigel Bark; RA Hyman
Cognitive deficits and psychopathology in elderly schizophrenic patients.
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 1997;5(1):31-42.
1995: Jean-Pierre Lindenmayer; D Da Silva; A Buendia; I Zylberman; M Vital-Herne
Tic-like syndrome after treatment with clozapine.
The American journal of psychiatry 1995;152(4):649.
1995: Jean-Pierre Lindenmayer; S Grochowski; R B Hyman
Five factor model of schizophrenia: replication across samples.
Schizophrenia research 1995;14(3):229-34.
1995: Jean-Pierre Lindenmayer; R Bernstein-Hyman; S Grochowski; Nigel Bark
Psychopathology of Schizophrenia: initial validation of a 5-factor model.
Psychopathology 1995;28(1):22-31.
1995: Jean-Pierre Lindenmayer
New pharmacotherapeutic modalities for negative symptoms in psychosis.
Acta psychiatrica Scandinavica. Supplementum 1995;388():15-9.
1994: Jean-Pierre Lindenmayer; R Bernstein-Hyman; S Grochowski
Five-factor model of schizophrenia. Initial validation.
The Journal of nervous and mental disease 1994;182(11):631-8.
1994: Daniel C Javitt; I Zylberman; Stephen R Zukin; Uriel Heresco-Levy; Jean-Pierre Lindenmayer
Amelioration of negative symptoms in schizophrenia by glycine.
The American journal of psychiatry 1994;151(8):1234-6.
1994: Jean-Pierre Lindenmayer; S Grochowski; L Mabugat
Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics.
Journal of clinical psychopharmacology 1994;14(3):201-4.
1994: J H Fields; S Grochowski; Jean-Pierre Lindenmayer; S R Kay; D Grosz; R B Hyman; G Alexander
Assessing positive and negative symptoms in children and adolescents.
The American journal of psychiatry 1994;151(2):249-53.
1994: Jean-Pierre Lindenmayer; R Bernstein-Hyman; S Grochowski
A new five factor model of schizophrenia.
The Psychiatric quarterly 1994;65(4):299-322.
1992: Nigel Bark; Jean-Pierre Lindenmayer
Ineffectiveness of clomipramine for obsessive-compulsive symptoms in a patient with schizophrenia.
The American journal of psychiatry 1992;149(1):136-7.
1991: Jean-Pierre Lindenmayer; S Grochowski; S R Kay
Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms.
Comprehensive psychiatry 1991;32(6):528-33.
1991: S R Kay; Jean-Pierre Lindenmayer
Stability of psychopathology dimensions in chronic schizophrenia: response to clozapine treatment.
Comprehensive psychiatry 1991;32(1):28-35.
1989: S R Kay; L A Opler; Jean-Pierre Lindenmayer
The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation.
The British journal of psychiatry. Supplement 1989;(7):59-67.
1989: Jean-Pierre Lindenmayer; S R Kay
Depression, affect and negative symptoms in schizophrenia.
The British journal of psychiatry. Supplement 1989;(7):108-14.